- Home
- AKRO vs SOC Comparison
AKRO vs SOC Comparison
Compare AKRO & SOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- SOC
- Stock Information
- Founded
- AKRO 2017
- SOC 2020
- Country
- AKRO United States
- SOC United States
- Employees
- AKRO N/A
- SOC N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- SOC
- Sector
- AKRO Health Care
- SOC
- Exchange
- AKRO Nasdaq
- SOC Nasdaq
- Market Cap
- AKRO 2.2B
- SOC 2.1B
- IPO Year
- AKRO 2019
- SOC N/A
- Fundamental
- Price
- AKRO $29.53
- SOC $20.77
- Analyst Decision
- AKRO Strong Buy
- SOC Buy
- Analyst Count
- AKRO 8
- SOC 3
- Target Price
- AKRO $46.83
- SOC $25.00
- AVG Volume (30 Days)
- AKRO 535.2K
- SOC 1.2M
- Earning Date
- AKRO 11-08-2024
- SOC 11-14-2024
- Dividend Yield
- AKRO N/A
- SOC N/A
- EPS Growth
- AKRO N/A
- SOC N/A
- EPS
- AKRO N/A
- SOC N/A
- Revenue
- AKRO N/A
- SOC N/A
- Revenue This Year
- AKRO N/A
- SOC N/A
- Revenue Next Year
- AKRO N/A
- SOC $606.07
- P/E Ratio
- AKRO N/A
- SOC N/A
- Revenue Growth
- AKRO N/A
- SOC N/A
- 52 Week Low
- AKRO $15.32
- SOC $10.11
- 52 Week High
- AKRO $37.00
- SOC $28.67
- Technical
- Relative Strength Index (RSI)
- AKRO 46.87
- SOC 50.62
- Support Level
- AKRO $28.45
- SOC $19.72
- Resistance Level
- AKRO $31.41
- SOC $22.05
- Average True Range (ATR)
- AKRO 1.29
- SOC 1.37
- MACD
- AKRO -0.15
- SOC 0.04
- Stochastic Oscillator
- AKRO 37.64
- SOC 52.27
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
About SOC Sable Offshore Corp. Common Stock
Sable Offshore Corp is a Houston-based independent upstream company focused on responsibly developing the prolific Santa Ynez Unit in federal waters offshore California.